|By PR Newswire||
|February 4, 2014 01:00 PM EST||
HONOLULU, Feb. 4, 2014 /PRNewswire/ -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded Hawaii Biotech, Inc. a grant to continue the development of anthrax anti-toxin drugs. The small molecule inhibitors under development block anthrax lethal toxin. The award has a first-year period of performance, through Q1 2014, valued at $1.1 million. The grant for the full five-year period equals $7.4 million.
Under this award, the Hawaii Biotech team will continue screening potent anti-toxin small molecules to block the action of lethal factor, the protease component of lethal toxin produced by Bacillus anthracis. This grant will support the improvement of current lethal factor inhibitors, which have demonstrated efficacy in animal models of post exposure inhalation of anthrax, as drug candidates. The safety, stability and bioavailability of these candidates will be improved with the goal of use in humans as an antidote to anthrax lethal factor intoxication.
"Research and development of vaccines and treatments to protect against infectious diseases will help keep our families and communities healthy and safe," Senator Brian Schatz said. "Hawaii Biotech is doing important work to find vaccines for some of the biggest global health threats, like anthrax, and this grant will help give them the resources they need. Achieving this competitive grant highlights Hawaii's continued growth in the high-level research and development community."
"Our team is pleased to be able to continue our anti-toxin development work at Hawaii Biotech, where we started this program several years ago," said Dr. Alan Johnson, the principal investigator. Dr. Elliot Parks, CEO of Hawaii Biotech, added, "This NIAID grant allows Hawaii Biotech to build our drug development capabilities to match our strong vaccine development franchise. In doing so, we hope to help protect the public against biological agents that might be used in an act of bioterrorism."
About Hawaii Biotech, Inc. (HBI):
Hawaii Biotech is a privately held biotechnology company focused on the development of prophylactic vaccines for established and emerging infectious diseases and anti-toxin drugs for biological threats. HBI has developed proprietary expertise in the production of recombinant proteins that have application to the manufacture of safe and effective vaccines, diagnostic kits and as research tools. HBI completed successful first-in-human Phase 1 clinical studies with both West Nile virus and dengue vaccines in healthy human subjects. HBI is currently engaged in the development of a product pipeline of recombinant subunit vaccines, including vaccine candidates for West Nile virus, tick-borne flavivirus, malaria, Crimean-Congo hemorrhagic fever and discovery of small molecule anti-toxin drugs for anthrax and botulism. HBI, founded in Hawaii in 1982, is headquartered in suburban Honolulu. For more information, please visit: www.hibiotech.com
About Anthrax Toxin:
Anthrax disease results from infection by the Gram-positive bacteria Bacillus anthracis. While infection via a wound or by ingestion of contaminated foodstuffs is often not life threatening, the mortality rate for inhalation anthrax can approach 100%, if left untreated. Once inhaled, the spores germinate and the vegetative bacteria disseminates throughout the body. In addition to causing septicemia, the bacteria secretes two major toxins, edema toxin and lethal toxin, which cripple the body's ability to fight the infection and can cause tissue damage. Although B. anthracis spores are found naturally in soils worldwide, the greatest danger to the public in developed countries results from the potential use of this pathogen as a weapon of bioterrorism. Anthrax has been designated a Category A biodefense agent by the Centers for Disease Control and Prevention. The threat from anthrax was clearly demonstrated by the 2001 bioterrorism attack which delivered spores using the US mail. Of the individuals diagnosed with inhalation anthrax after that attack, 45% died from the disease despite receiving intensive antibiotic and supportive medical treatment. For more information, please visit: http://www.cdc.gov/anthrax/index.html
SOURCE Hawaii Biotech, Inc.
DevOps has often been described in terms of CAMS: Culture, Automation, Measuring, Sharing. While we’ve seen a lot of focus on the “A” and even on the “M”, there are very few examples of why the “C" is equally important in the DevOps equation. In her session at @DevOps Summit, Lori MacVittie, of F5 Networks, will explore HTTP/1 and HTTP/2 along with Microservices to illustrate why a collaborative culture between Dev, Ops, and the Network is critical to ensuring success.
Oct. 10, 2015 12:00 PM EDT Reads: 170
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and containers together help companies achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, will review the current landscape of...
Oct. 10, 2015 12:00 PM EDT
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi's VP Business Development and Engineering, will explore the IoT cloud-based platform technologies driv...
Oct. 10, 2015 12:00 PM EDT Reads: 158
In their session at DevOps Summit, Asaf Yigal, co-founder and the VP of Product at Logz.io, and Tomer Levy, co-founder and CEO of Logz.io, will explore the entire process that they have undergone – through research, benchmarking, implementation, optimization, and customer success – in developing a processing engine that can handle petabytes of data. They will also discuss the requirements of such an engine in terms of scalability, resilience, security, and availability along with how the archi...
Oct. 10, 2015 12:00 PM EDT Reads: 410
DevOps is gaining traction in the federal government – and for good reasons. Heightened user expectations are pushing IT organizations to accelerate application development and support more innovation. At the same time, budgetary constraints require that agencies find ways to decrease the cost of developing, maintaining, and running applications. IT now faces a daunting task: do more and react faster than ever before – all with fewer resources.
Oct. 10, 2015 12:00 PM EDT Reads: 419
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction....
Oct. 10, 2015 11:30 AM EDT Reads: 284
Docker is hot. However, as Docker container use spreads into more mature production pipelines, there can be issues about control of Docker images to ensure they are production-ready. Is a promotion-based model appropriate to control and track the flow of Docker images from development to production? In his session at DevOps Summit, Fred Simon, Co-founder and Chief Architect of JFrog, will demonstrate how to implement a promotion model for Docker images using a binary repository, and then show h...
Oct. 10, 2015 11:00 AM EDT Reads: 226
The last decade was about virtual machines, but the next one is about containers. Containers enable a service to run on any host at any time. Traditional tools are starting to show cracks because they were not designed for this level of application portability. Now is the time to look at new ways to deploy and manage applications at scale. In his session at @DevOpsSummit, Brian “Redbeard” Harrington, a principal architect at CoreOS, will examine how CoreOS helps teams run in production. Attende...
Oct. 10, 2015 11:00 AM EDT Reads: 1,281
There will be 20 billion IoT devices connected to the Internet soon. What if we could control these devices with our voice, mind, or gestures? What if we could teach these devices how to talk to each other? What if these devices could learn how to interact with us (and each other) to make our lives better? What if Jarvis was real? How can I gain these super powers? In his session at 17th Cloud Expo, Chris Matthieu, co-founder and CTO of Octoblu, will show you!
Oct. 10, 2015 11:00 AM EDT Reads: 124
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of at least three separate application components: the software embedded in the device, the backend big-data service, and the mobile application for the end user's controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/...
Oct. 10, 2015 11:00 AM EDT Reads: 326
As a company adopts a DevOps approach to software development, what are key things that both the Dev and Ops side of the business must keep in mind to ensure effective continuous delivery? In his session at DevOps Summit, Mark Hydar, Head of DevOps, Ericsson TV Platforms, will share best practices and provide helpful tips for Ops teams to adopt an open line of communication with the development side of the house to ensure success between the two sides.
Oct. 10, 2015 11:00 AM EDT Reads: 639
Clutch is now a Docker Authorized Consulting Partner, having completed Docker's certification course on the "Docker Accelerator for CI Engagements." More info about Clutch's success implementing Docker can be found here. Docker is an open platform for developers and system administrators to build, ship and run distributed applications. With Docker, IT organizations shrink application delivery from months to minutes, frictionlessly move workloads between data centers and the cloud and achieve 2...
Oct. 10, 2015 10:45 AM EDT Reads: 524
Mobile messaging has been a popular communication channel for more than 20 years. Finnish engineer Matti Makkonen invented the idea for SMS (Short Message Service) in 1984, making his vision a reality on December 3, 1992 by sending the first message ("Happy Christmas") from a PC to a cell phone. Since then, the technology has evolved immensely, from both a technology standpoint, and in our everyday uses for it. Originally used for person-to-person (P2P) communication, i.e., Sally sends a text...
Oct. 10, 2015 10:15 AM EDT Reads: 336
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
Oct. 10, 2015 10:00 AM EDT Reads: 180
The IoT market is on track to hit $7.1 trillion in 2020. The reality is that only a handful of companies are ready for this massive demand. There are a lot of barriers, paint points, traps, and hidden roadblocks. How can we deal with these issues and challenges? The paradigm has changed. Old-style ad-hoc trial-and-error ways will certainly lead you to the dead end. What is mandatory is an overarching and adaptive approach to effectively handle the rapid changes and exponential growth.
Oct. 10, 2015 10:00 AM EDT Reads: 256